Loading
Prostatic Neoplasms / Xenograft Model Antitumor Assays / Cell Line, Tumor · Journal article
Gut Microbes · June 7, 2026
Encouraging direction, but not yet definitive.
This preclinical investigation demonstrates that gut bacteria—particularly Escherichia coli—metabolize flutamide into inactive derivatives (FLU-6, FLU-9, FLU-5) via nitroreduction and acetylation pathways, and that oral E. coli administration reduced flutamide efficacy in a mouse xenograft model. Clinical sample analysis revealed substantial interpatient variability in microbial metabolic capability, stratifying patients into high and low metabolic subgroups, suggesting a mechanistic basis for treatment heterogeneity and a potential target for personalized optimization of antiandrogen therapy.
Preclinical mechanistic study: in vitro bacterial genetics, mouse xenograft model, and clinical sample observational analysis. Xenograft: prostate cancer model (specific line and host strain not specified in excerpt). In vitro: prostate cancer cell lines. Clinical: patient samples with stratification into high and low metabolic capability groups (demographics and inclusion criteria not detailed in excerpt). Intervention: Oral administration of E. coli in xenograft model; flutamide treatment; antibiotic intervention to deplete gut microbiota. Compared with: Untreated or E. coli-treated xenografts; antibiotic-treated vs. control mice. Zhejiang Cancer Hospital and affiliated institutions, Hangzhou, China.
Gut bacteria metabolize flutamide into FLU-6 (nitroreduction product) and FLU-9 (acetylation product), with E. coli nfsA and nfsB genes essential for nitroreduction Synthesized FLU-6, FLU-9, and FLU-5 showed no anticancer activity in prostate cancer cell lines In xenograft model, oral E. coli administration diminished flutamide efficacy by altering its metabolic profile
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest that gut microbiota-mediated flutamide inactivation may contribute to clinical treatment failure and interindividual variability in response. Microbiota profiling or metabolic testing could potentially identify patients at risk of poor flutamide response and enable strategies such as targeted antibiotic co-treatment, though clinical validation is required before implementation.
Mechanistic preclinical study with xenograft and clinical sample data identifying gut microbial metabolism as a contributor to flutamide resistance, with potential for personalized therapy but lacking clinical trial evidence of efficacy.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest that gut microbiota-mediated flutamide inactivation may contribute to clinical treatment failure and interindividual variability in response. Microbiota profiling or metabolic testing could potentially identify patients at risk of poor flutamide response and enable strategies such as targeted antibiotic co-treatment, though clinical validation is required before implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Endocrine drugs serve as the cornerstone of prostate cancer treatment. Flutamide, a representative first-generation antiandrogen, has been relegated to the treatment of recurrent prostate cancer due to novel drug development and therapeutic resistance. Our study shows the gut microbiota contributes to this resistance. Specifically, gut bacteria metabolize Flutamide into FLU-6 (a nitroreduction product) and FLU-9 (an acetylation product), involving species like Escherichia coli. Gene knockout revealed E. coli nfsA and nfsB as essential for Flutamide nitroreduction, while heterologous expression confirmed acetyltransferases mediate the production of acetylated metabolites. In the antibiotic-treated mouse model, antibiotic intervention significantly reduced microbial metabolites of Flutamide. In addition, FLU-6 was further metabolized by the host into FLU-5. Synthesized FLU-6, FLU-9, and FLU-5 showed no anticancer activity in prostate cancer cell lines. In a xenograft model, oral administration of E. coli diminished Flutamide's efficacy by altering its metabolic profile. Clinical sample analysis revealed substantial interpatient variability, and patients could be categorized into subgroups with high or low metabolic capability. These findings provide new insights into personalized prostate cancer therapy, highlight the role of the gut microbiota in Flutamide response and suggest a strategy for optimizing antiandrogen treatments.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.